Cardiometabolic Health
9 articles on Cardiometabolic Health, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Weight Loss: What Happens When You Stop Semaglutide or Tirzepatide?
A comprehensive analysis of recent data shows that stopping GLP-1 medications like Ozempic and Wegovy often leads to weight regain and a return of cardiometabolic risk markers. Here is what you need to know about long-term outcomes and maintenance strategies.
7 min read
Biggest Mistake GLP-1 Users Make, Doctor Says
A surge in GLP-1 drug use has millions turning to shots like Ozempic or pills like Wegovy for weight loss, but doctors warn of a critical error. The biggest mistake? Thinking the prescription is enough without lifestyle changes. A study of 98,000 veterans shows combining GLP-1s with healthy habits slashes cardiovascular risks by 43%.
6 min read
Experts Stress Holistic Approach to Semaglutide for Weight Management
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
6 min read
GLP-1 Drugs Surge: Healthy Habits Still Essential for Best Results
Demand for GLP-1 drugs like Wegovy and Zepbound is booming, with 1 in 8 Americans now using them. But experts warn: medication alone isn't enough—pairing with healthy habits like protein-rich meals, exercise, and sleep amplifies weight loss and health gains, per recent studies.
6 min read
GP's Surprising Mounjaro Effects: Weight Loss and Mood Shifts After 3 Months
A 33-year-old GP tried Mounjaro for obesity and was stunned by more than just weight loss—his 'food noise' vanished, alcohol interest dropped, and mood stabilized. After shedding almost two stone in three months, urges returned upon stopping, highlighting obesity's chronic nature. Now back on 5mg, he emphasizes long-term strategies beyond medication.
5 min read
How GLP-1 Weight Loss Drugs Revolutionized Obesity: Lessons Learned
GLP-1 weight loss drugs such as Wegovy and Zepbound have revolutionized obesity care, leading to up to 20% body weight reduction over 72 weeks. These therapies challenge old views of obesity as mere lifestyle failure, highlighting brain hunger centers, genetics, and hormones. From chronic disease recognition to equitable access, here's how they've reshaped treatment.
5 min read
Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
5 min read
Weight Loss Drugs Cessation Linked to Regain and Cardiac Hazards
A comprehensive analysis published in The BMJ reveals that discontinuing weight loss drugs leads to an average monthly regain of 0.4 kg, with full weight and cardiometabolic risks returning within two years. This regain occurs nearly four times faster than after dietary and lifestyle interventions, raising questions about the drugs' long-term effectiveness. Experts emphasize combining medications with healthy habits for sustainable obesity control.
3 min read
Reduced Gestational Diabetes Risk Observed with GLP-1 Use Before Pregnancy
A retrospective cohort study revealed that women taking GLP-1 receptor agonists before pregnancy exhibited a lower incidence of gestational diabetes. However, the study also indicated a potentially higher risk of pre-eclampsia in this group. These findings warrant further investigation due to the small sample size and potential confounding factors.
4 min read